Feedback / Questions
Xervyteg (MaaT013) - MaaT Pharma
https://www.businesswire.com/news/home/20251208466457/en/MaaT-Pharma-Presents-Pivotal-ARES-Phase-3-Results-for-MaaT013-Xervyteg-in-Acute-GvHD-at-ASH-2025-Annual-Congress-and-Announces-54-1-Year-Overall-Survival
Dec 8, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next